# Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

> **NCT02376985** · PHASE3 · COMPLETED · sponsor: **Comprehensive Support Project for Oncology Research** · enrollment: 174 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Oral management
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02376985
- **Lead sponsor:** Comprehensive Support Project for Oncology Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-26
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-10-16
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02376985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02376985, "Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02376985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*